Edmond Y Huang1, Takuya Inoue, Vanessa A Leone, Sushila Dalal, Ketrija Touw, Yunwei Wang, Mark W Musch, Betty Theriault, Kazuhide Higuchi, Sharon Donovan, Jack Gilbert, Eugene B Chang. 1. *Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois; †2nd Department of Internal Medicine, Osaka Medical College, Takatsuki, Japan; ‡Department of Surgery, University of Chicago, Chicago, Illinois; §Department of Food Science and Human Nutrition, University of Illinois, Urbana, Illinois; ‖Biosciences Division, Argonne National Laboratory, Argonne, Illinois; ¶Department of Ecology and Evolution, University of Chicago, Chicago, Illinois; **Marine Biological Laboratory, Woods Hole, Massachusetts; and ††College of Environmental and Resource Sciences, Zhejiang University, Hangzhou, China.
Abstract
BACKGROUND: Commensal gut microbiota play an important role in regulating metabolic and inflammatory conditions. Reshaping intestinal microbiota through pharmacologic means may be a viable treatment option. We sought to delineate the functional characteristics of glucocorticoid-mediated alterations on gut microbiota and their subsequent repercussions on host mucin regulation and colonic inflammation. METHODS: Adult male C57Bl/6 mice, germ-free, Muc2-heterozygote (±), or Muc2-knockout (-/-) were injected with dexamethasone, a synthetic glucocorticoid, for 4 weeks. Fecal samples were collected for gut microbiota analysis through 16S rRNA terminal restriction fragment length polymorphism and amplicon sequencing. Intestinal mucosa was collected for mucin gene expression studies. Germ-free mice were conventionalized with gut microbes from treated and nontreated groups to determine their functional capacities in recipient hosts. RESULTS: Exposure to dexamethasone in wild-type mice led to substantial shifts in gut microbiota over a 4-week period. Furthermore, a significant downregulation of colonic Muc2 gene expression was observed after treatment. Muc2-knockout mice harbored a proinflammatory environment of gut microbes, characterized by the increase or decrease in prevalence of specific microbiota populations such as Clostridiales and Lactobacillaceae, respectively. This colitogenic phenotype was transmissible to IL10-knockout mice, a genetically susceptible model of colonic inflammatory disorders. Microbiota from donors pretreated with dexamethasone, however, ameliorated symptoms of inflammation. CONCLUSIONS: Commensal gut bacteria may be a key mediator of the anti-inflammatory effects observed in the large intestine after glucocorticoid exposure. These findings underscore the notion that intestinal microbes comprise a "microbial organ" essential for host physiology that can be targeted by therapeutic approaches to restore intestinal homeostasis.
BACKGROUND: Commensal gut microbiota play an important role in regulating metabolic and inflammatory conditions. Reshaping intestinal microbiota through pharmacologic means may be a viable treatment option. We sought to delineate the functional characteristics of glucocorticoid-mediated alterations on gut microbiota and their subsequent repercussions on host mucin regulation and colonic inflammation. METHODS: Adult male C57Bl/6 mice, germ-free, Muc2-heterozygote (±), or Muc2-knockout (-/-) were injected with dexamethasone, a synthetic glucocorticoid, for 4 weeks. Fecal samples were collected for gut microbiota analysis through 16S rRNA terminal restriction fragment length polymorphism and amplicon sequencing. Intestinal mucosa was collected for mucin gene expression studies. Germ-free mice were conventionalized with gut microbes from treated and nontreated groups to determine their functional capacities in recipient hosts. RESULTS: Exposure to dexamethasone in wild-type mice led to substantial shifts in gut microbiota over a 4-week period. Furthermore, a significant downregulation of colonic Muc2 gene expression was observed after treatment. Muc2-knockout mice harbored a proinflammatory environment of gut microbes, characterized by the increase or decrease in prevalence of specific microbiota populations such as Clostridiales and Lactobacillaceae, respectively. This colitogenic phenotype was transmissible to IL10-knockout mice, a genetically susceptible model of colonic inflammatory disorders. Microbiota from donors pretreated with dexamethasone, however, ameliorated symptoms of inflammation. CONCLUSIONS: Commensal gut bacteria may be a key mediator of the anti-inflammatory effects observed in the large intestine after glucocorticoid exposure. These findings underscore the notion that intestinal microbes comprise a "microbial organ" essential for host physiology that can be targeted by therapeutic approaches to restore intestinal homeostasis.
Authors: C Hanski; M Hofmeier; A Schmitt-Gräff; E Riede; M L Hanski; F Borchard; E Sieber; F Niedobitek; H D Foss; H Stein; E O Riecken Journal: J Pathol Date: 1997-08 Impact factor: 7.996
Authors: M Blank; E Klussmann; S Krüger-Krasagakes; A Schmitt-Gräff; M Stolte; G Bornhoeft; H Stein; P X Xing; I F McKenzie; C P Verstijnen Journal: Int J Cancer Date: 1994-11-01 Impact factor: 7.396
Authors: Jonathan D Schepper; Fraser L Collins; Naiomy Deliz Rios-Arce; Sandi Raehtz; Laura Schaefer; Joseph D Gardinier; Robert A Britton; Narayanan Parameswaran; Laura R McCabe Journal: J Bone Miner Res Date: 2019-01-28 Impact factor: 6.741
Authors: V Morampudi; U Dalwadi; G Bhinder; H P Sham; S K Gill; J Chan; K S B Bergstrom; T Huang; C Ma; K Jacobson; D L Gibson; B A Vallance Journal: Mucosal Immunol Date: 2016-01-27 Impact factor: 7.313